Global Rheumatoid Arthritis Drugs Market

Global Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By Drug Class(Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs), By Route of Administration(Oral, Parenteral), By Sales Channel(Prescription-based Drugs, Over-the-counter Drugs), By Molecule(Pharmaceuticals and Biopharmaceuticals) - Industry Forecast 2024-2031

Report ID: SQSG35I2003 | Region: Global | Published Date: April, 2024
Pages: 242 | Tables: 115 | Figures: 69

Global Rheumatoid Arthritis Drugs Market Regional Insights

North America holds majority share and is likely to maintain its dominant position in the Global Rheumatoid Arthritis Drugs market over the forecast period. Due to the presence of a large population base susceptible to rheumatoid arthritis, increased public awareness about the use and benefits of these drugs, development of the R&D sector, rise in healthcare reforms, and increase in rheumatoid arthritis drug adoption, Asia-Pacific presents lucrative opportunities for key players operating in the market. Furthermore, the rise in geriatric population and increased demand for DMARDs contribute to global market growth. Furthermore, the increased focus of top manufacturers on increasing their geographical presence in rising Asia-Pacific countries in order to acquire a large portion of the Global Rheumatoid Arthritis Drugs market is likely to boost growth.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Rheumatoid Arthritis Drugs Market size was valued at USD 59.031 billion in 2019 and is poised to grow from USD 60.02 billion in 2023 to USD 70 billion by 2031, growing at a CAGR of 1.72% in the forecast period (2024-2031).

Global rheumatoid arthritis drugs market has become moderately competitive. This is partly because there are a number of new drugs available that can help to treat the condition. However, it is also due to the fact that existing drugs are being marketed in a more aggressive way. This means that companies are investing more in marketing their products, which in turn leads to higher sales volumes. The major players in this market are focusing on developing new and innovative products that can address the needs of patients. This is expected to drive the growth of the rheumatoid arthritis drugs market over the forecast period. 'Pfizer Inc.', 'Johnson & Johnson Services, Inc.', 'AbbVie Inc.', 'Amgen Inc.', 'Bristol Myers Squibb Co.', 'Celgene Corporation', 'Eli Lilly and Company', 'F. Hoffmann-La Roche AG', 'GlaxoSmithKline plc', 'Merck & Co., Inc.', 'Novartis International AG', 'Sanofi S.A.UCB S.A.Biogen Idec Inc.Gilead Sciences, Inc.Astellas Pharma Inc.Daiichi Sankyo Company LimitedEisai Co., Ltd.Ipsen S.A.Kyowa Kirin Co., Ltd.'

Rheumatoid arthritis drugs are expensive and patients often end up paying up to USD 30,000 on the medication each year. It has also been found that most of the patients have to cover the expenses out of their pockets and it can be reimbursed by insurance providers, depending on the coverage amount. Despite the insurance coverage, patient has to pay up to 30% of the cost on their own.

Increasing prevalence of rheumatoid arthritis among elderly population. In addition to this, a shift from symptom management to slowing the progression of the disease is driving the growth of the rheumatoid arthritis drugs market.

North America holds majority share and is likely to maintain its dominant position in the Global Rheumatoid Arthritis Drugs market over the forecast period. Due to the presence of a large population base susceptible to rheumatoid arthritis, increased public awareness about the use and benefits of these drugs, development of the R&D sector, rise in healthcare reforms, and increase in rheumatoid arthritis drug adoption, Asia-Pacific presents lucrative opportunities for key players operating in the market. Furthermore, the rise in geriatric population and increased demand for DMARDs contribute to global market growth. Furthermore, the increased focus of top manufacturers on increasing their geographical presence in rising Asia-Pacific countries in order to acquire a large portion of the Global Rheumatoid Arthritis Drugs market is likely to boost growth.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Global Rheumatoid Arthritis Drugs Market

Report ID: UCMIG35I2157 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

Congestive Heart Failure Drugs Market
Buy Now GET FREE SAMPLE
Global Rheumatoid Arthritis Drugs Market

Report ID: SQSG35I2047 | Region: Global | Published Date: April, 2024 | Pages: 225 | Tables: 102 | Figures: 76

Global CBD-infused Products Market
Buy Now GET FREE SAMPLE
Global Rheumatoid Arthritis Drugs Market

Report ID: UCMIG35I2154 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

Small Molecule Innovator CDMO Market
Buy Now GET FREE SAMPLE
Global Rheumatoid Arthritis Drugs Market

Report ID: SQSG35I2028 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: 96 | Figures: 76

Global Gastroenterology Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Rheumatoid Arthritis Drugs Market

Product ID: SQSG35I2003

$5,300
BUY NOW GET FREE SAMPLE